Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Pfizer said on Monday former head of the US Food and Drug Administration's drug center, Patrizia Cavazzoni, will join the ...
The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
1d
GlobalData on MSNPfizer sets sights on Summit’s bispecific in combo with its ADCsSummit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results